Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic DermatitisBusiness Wire • 10/15/21
Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?The Motley Fool • 10/15/21
J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study FindsForbes • 10/14/21
J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggestsCNBC • 10/13/21
Pfizer (PFE) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 10/11/21
4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 PillThe Motley Fool • 10/11/21